Cargando…
Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488898/ https://www.ncbi.nlm.nih.gov/pubmed/34289985 http://dx.doi.org/10.1183/16000617.0010-2021 |
_version_ | 1784792763864186880 |
---|---|
author | Chalmers, James D. van Ingen, Jakko van der Laan, Roald Herrmann, Jean-Louis |
author_facet | Chalmers, James D. van Ingen, Jakko van der Laan, Roald Herrmann, Jean-Louis |
author_sort | Chalmers, James D. |
collection | PubMed |
description | Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases. |
format | Online Article Text |
id | pubmed-9488898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94888982022-11-14 Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections Chalmers, James D. van Ingen, Jakko van der Laan, Roald Herrmann, Jean-Louis Eur Respir Rev Review Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases. European Respiratory Society 2021-07-21 /pmc/articles/PMC9488898/ /pubmed/34289985 http://dx.doi.org/10.1183/16000617.0010-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Review Chalmers, James D. van Ingen, Jakko van der Laan, Roald Herrmann, Jean-Louis Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title_full | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title_fullStr | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title_full_unstemmed | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title_short | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
title_sort | liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488898/ https://www.ncbi.nlm.nih.gov/pubmed/34289985 http://dx.doi.org/10.1183/16000617.0010-2021 |
work_keys_str_mv | AT chalmersjamesd liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections AT vaningenjakko liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections AT vanderlaanroald liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections AT herrmannjeanlouis liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections |